Rohit Bose is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 54 publications with 3,429 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1825 4th St
San Francisco, CA 941432350
Telephone
415-476-4616Provider last certified this registry record 9 Dec 2019.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202520 payments
- Exelixis Inc.Program year20251 payment
- Caris MPI, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.3%Gonadotropin Releasing Hormone Receptor Antagonist28%Orgovyx100%Part D<11 patientsCytochrome P450 17A1 Inhibitor24.9%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
33.7%Corticosteroid33.7%Prednisone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2018–2023 per NIH RePORTER. The latest:
- Simulating Ancestrally Unbiased Tumor Evolution To Interrogate Drug Resistance
University of California, San Francisco
FY2023$1,453,500DP2CA290244 - Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate Oncogenesis
University of California, San Francisco
FY2022$260,330K08CA226348 - Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate Oncogenesis
University of California, San Francisco
FY2021$260,330K08CA226348
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Stochastically Emergent Tumors offer in vivo whole genome interrogation of cancer evolution from non-malignant precursors
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”